The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| RefleXion Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $505.72M | Series F | 11/15/2023 | $106.71M | $874.99M | $1.50 | The Rise Fund, Pictet, Square Point Capital, Ally Bridge Group, Pfizer, Johnson & Johnson, T. Rowe Price, Venrock, Catalio Capital Management, Hillenbrand Capital Partners | |||||
| SetPoint Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $303.01M | Series D | 8/11/2025 | $115M | $471.62M | $1.51 | Elevage Medical Technologies, Ally Bridge Group, Northwell Health, SPRIG Equity, Norwest Venture Partners, New Enterprise Associates, Viking Global Investors, Action Potential Venture Capital, Abbott, Boston Scientific, Euclidean Capital, Richard King Mellon Foundation, Morgenthaler Ventures, ShangBay Capital, Ascendum Capital, Catalio Capital Management, Gilmartin Capital, Midas Capital | |||||
| Tessera Therapeutics | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $587.85M | Series D | 12/1/2025 | $200M | $668.33M | $5.18 | Bill & Melinda Gates Foundation, Regeneron | |||||
| Valo | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $406.25M | Series B | 3/9/2021 | $310M | $919.92M | $5.88 | PSP Investments, Flagship Pioneering, Invus Public Equities, HBM Healthcare Investments, Atinum Investment, Mirae Asset Capital, Koch Disruptive Technologies | |||||
| Viz.ai | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $273.45M | Series D | 3/22/2023 | $120M | $1.28B | $6.35 | Tiger Global Management, Insight Partners, Scale Venture Partners, Kleiner Perkins, Threshold Ventures, GV, Sozo Ventures, CRV, Susa Ventures, Canadian Imperial Bank of Commerce | |||||
| Avenzo Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $445.85M | Series B | 9/22/2025 | $60M | $616.96M | $2.22 | OrbiMed, SR One, Longwood Fund, Foresite Capital, Lilly Asia Ventures, Surveyor Capital, NEA, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital | |||||
| Boundless Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $756.15M | Series C | 5/16/2023 | $100M | $273.76M | $0.70 | Bayer, RA Capital Management, Sectoral Asset Management, Piper Heartland, Healthcare Capital | |||||
| Cala Health | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Capstan Therapeutics | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $845M | Series B | 3/20/2024 | $175M | $525.33M | $3.37 | RA Capital Management, Forbion, Johnson & Johnson, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly, Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, Vida Ventures | |||||
| Encoded Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $945.89M | Series F | 8/3/2026 | $275M | $629.69M | $3.40 | Undisclosed Investors | |||||
| Firefly Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $240.86M | Series C | 10/25/2024 | $60M | $348.01M | $6.26 | Undisclosed Investors | |||||
| Georgiamune | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $167.69M | Series B-1 | 7/16/2026 | $64.09M | $407.96M | $11.11 | Undisclosed Investors | |||||
| Ginkgo Bioworks | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $785.53M | Series E | 5/28/2020 | $360M | $4.89B | $150.19 | T. Rowe Price, Allen & Company, Baillie Gifford, Cascade Investment, General Atlantic, Reshape Holdings, Viking Global Investors, Illumina | |||||
| Glooko | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $521.83M | Series F | 10/10/2024 | $100M | $475.64M | $2.42 | Georgian Partners, Health Catalyst Capital, Canaan | |||||
| GT Medical Technologies | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $219.98M | Series E | 6/9/2026 | $100M | $364.93M | $2.61 | Viking Global Investors, MVM Partners, Gilde Healthcare, Evidity Health Capital, MedTech Venture Partners, FemHealth Ventures | |||||
| Hazel Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $364.29M | Series E | 6/9/2026 | $99.03M | $396.96M | $2.40 | Undisclosed Investors | |||||
| HealthJoy | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $87.95M | Series D | 10/27/2022 | $35M | $179.66M | $2.70 | Valspring Capital, Endeavour Vision, CIBC Innovation Banking, U.S. Venture Partners, Brandon Cruz, Clint Jones, Health Velocity Capital, Nueterra Capital, EPIC Ventures | |||||
| Kriya Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $940.5M | Series D | 9/10/2025 | $320.82M | $1.67B | $10.34 | Patient Square Capital, Premji Invest, Peter Thiel, Narya Capital, The T1D Fund | |||||
| Medeor Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Obsidian Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $329.03M | Series C | 4/3/2024 | $160.5M | $480.83M | $1.90 | Wellington Management, Foresite Capital, Janus Henderson Investors, Novo Holdings, Paradigm BioCapital, RTW Investments, T. Rowe Price Associates, Woodline Partners, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCG Crossover Management, Samsara, Surveyor Capital | |||||
| Odyssey Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $413.6M | Series D | 9/10/2025 | $213.63M | $527.3M | $14.62 | Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG, Wedbush Healthcare Partners | |||||
| Ophelia | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $39.71M | Series AA | 3/7/2025 | $15M | $103.93M | $3.09 | Undisclosed Investor | |||||
| OSSIO | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Owkin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $279.77M | Series B-1 | 6/8/2022 | $50M | $1.46B | $45.70 | Bristol Myers Squibb | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.